The nuclear receptor superfamily includes retinoid, thyroid hormone, steroid and peroxisome proliferator-activated (PPAR) receptors. Unlike plasma membrane receptors that signal through second messengers, nuclear receptors can function directly as transcription factors that control gene transcription. A historical example of nuclear receptor ligands that activate these ''classical'' or ''genomic'' pathway to inhibit pain are the steroidal anti-inflammatory drugs. More recently, two isoforms of PPAR, namely PPARa and PPARc, have received significant interest as analgesic targets for chronic pain [4] . Administration of synthetic PPARa and PPARc ligands reduce behavioral signs of allodynia and hyperalgesia in a number of pain models [1, 6, 13] . Similarly, antihyperalgesic effects are produced by endogenously-generated PPAR activators. Of particular importance to pain research are the fatty acid ethanolamides, palmitoylethanolamide (PEA) and oleoylethanolamide (OEA), both of which bind with high affinity to PPARa [12] . In neurons, glia, and inflammatory cells, PEA and OEA are not stored, but rather are made on demand -endogenous levels are regulated by the relative activity of biosynthetic and degradative enzymes. Animal studies convincingly demonstrate that PEA exerts a broad spectrum pain inhibition that can be reversed with PPARa antagonists and this inhibition does not occur in deletion mutant mice lacking PPARa [6] . Fig. 1A illustrates a potential mechanism through which PPARa mediates the antihyperalgesic actions of PEA.
Palmitoylethanolamide is approved in some countries (e.g. Italy) as a dietary supplement in humans, and preliminary but intriguing clinical trials and case studies suggest that oral PEA is effective for a variety of pain syndromes [7] . Unfortunately, the analgesic potential of direct PPARa activators, synthetic or natural, has not been met. Due to the pleiotropic nature of PPAR action, currently available synthetic ligands designed to activate PPARa directly have yielded undesired off-target effects [8] . PEA is not very potent (doses close to 1 g are typically administered) and its analgesic efficacy (magnitude of pain reduction) is far from powerful, perhaps because PEA concentrations are not adequate in key target tissues. In this issue of Pain, Sasso et al. [11] provide a solution to this problem, with an approach that is designed to increase the intrinsic concentrations of PEA. Their compelling new strategy arises from a longstanding discovery that inhibition of fatty acid amine hydrolase (FAAH) increases levels of fatty acid ethanolamides (FAE), notably anandamide (Fig. 1A) . The anandamide, in turn, exerts an analgesic action at cannabinoids receptors. Not surprisingly, those findings led to an intensive effort towards the clinical development of FAAH inhibitors for chronic pain [2] . But in addition to FAAH, fatty acid ethanolamides can be hydrolyzed by an assortment of enzymes, notably N-acylethanolamine acid amidase (NAAA), the primary enzyme involved in the hydrolysis of PEA [15] . NAAA hydrolyzes PEA to palmitic acid and ethanolamine, with much greater efficacy and selectivity than FAAH -the latter efficiently hydrolyzes OEA in addition to anandamide (Fig. 1A) Fatty acid ethanolamides are formed and then released from membrane glycerophospholipids through the phosphodiesterasetransacylation pathway. Fig. 1A includes a simplified scheme of the most widely-accepted enzymatic pathways for FAE synthesis and degradation in neurons and immune cells. Fig. 1B illustrates that inflammatory injury suppresses the enzyme that generates fatty acid ethanolamides, thus stopping the production of FAEs, including PEA [16] . As illustrated in Fig. 1C , Sasso et al. [11] selectively inhibits NAAA, thus reinstating PEA concentrations. The resulting increase in PEA-mediated PPARa activation then generates antihyperalgesic actions, setting the stage for the development of a new pharmacotherapeutic target for chronic pain.
In many ways, the results of Sasso et al. [11] provide an instructive example of outstanding preclinical drug development, as they include: 1) measurement in skin and nerve show that the drug does what it was designed to do -namely return depleted PEA levels back to normal concentrations; 2) full time course of behavioral responses to topical ARN007, indicating a reasonably long duration of action; 3) establishment of a full dose-response relationship (1-30% topical solution) supporting a pharmacological target; 4) demonstration of antihyperalgesic effects in multiple pain models, suggesting broad-spectrum action; 5) studies in both mice and rats, which suggests generalization across species; 6) examination of multiple routes of administration, including topical administration, which suggest opportunities for clinical translation; 7) negative controls with cannabinoid receptor antagonists, which point to a PPAR rather than cannabinoid receptor mechanism of action; 8) positive controls showing that ARN007 is more efficacious than a high dose of gabapentin.
The finding that palmitoylethanolamide produces its antihyperalgesic effects through a PPARa mechanism was initially quite puzzling. The rapid actions in vivo described previously and also in the Sasso et al. [11] report do not fit with the time required for gene transcription following nuclear receptor activation. Responses mediated by the genomic pathways require time for pro-
